This chronic allergic reaction leads to continuous inflammation of the nasal passages, creating an environment where polyps ...

Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Full results have not yet been published, but according to Amgen findings showed treatment with tezepelumab statistically significantly and clinically meaningfully reduced the size of nasal polyps and ...

AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps. Chronic rhinosinusitis is a disorder characterised by ...

The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

A study published in Frontiers in Medicine reveals that chronic rhinosinusitis with and without nasal polyps is closely correlated with asthma.A study was done to investigate the ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

The tezepelumab data are clinically meaningful and offer patients with nasal polyps hope for a potential new treatment option that may reduce the burden on patients and healthcare systems.” ...

The tezepelumab data are clinically meaningful and offer patients with nasal polyps hope for a potential new treatment option that may reduce the burden on patients and healthcare systems." Sharon ...